Synopsis
Recognise the cognitive, visual, sleep, motor and autonomic signature of dementia with Lewy bodies, use indicative investigations when uncertainty matters, and treat symptoms while avoiding severe antipsychotic sensitivity and compounding orthostatic or cognitive harm.
- Core clinical features are marked cognitive fluctuation, recurrent well-formed visual hallucinations, REM sleep behaviour disorder and spontaneous parkinsonism.
- Early cognition often emphasises attention, executive and visuoperceptual dysfunction; prominent storage-memory loss may be less striking than in typical Alzheimer disease.
- Fluctuation means spontaneous variation in attention and alertness over minutes, hours or days, not simply good and bad months or delirium during infection.
- Ask about dream enactment years before cognitive diagnosis, including shouting, punching, falling from bed and injury to the person or bed partner.
- Supportive features include repeated falls, syncope, severe autonomic dysfunction, depression, apathy, hyposmia and marked sensitivity to dopamine-blocking antipsychotics.
- When parkinsonism begins before or within about one year of dementia, the clinical label is DLB; dementia arising after established Parkinson disease is termed Parkinson disease dementia.
- If clinical diagnosis remains uncertain, NICE recommends iodine-123 FP-CIT SPECT to assess striatal dopaminergic transporter uptake, while a normal scan does not absolutely exclude DLB.
- Offer donepezil or rivastigmine for mild to moderate DLB; these medicines may help cognition, fluctuation and hallucinations, with pulse, syncope, weight and gastrointestinal monitoring.
- Avoid antipsychotics whenever possible because they can worsen motor and cognitive symptoms and cause severe sensitivity; if risk or severe distress leaves no alternative, use specialist-led lowest exposure and frequent review.
- Levodopa may modestly improve disabling parkinsonism but can worsen hallucinations and confusion, so treatment goals and dose increments should be conservative.
Key red flags
Disproportionate sedation, confusion, immobility, rigidity, swallowing decline or autonomic instability after an antipsychotic is a major warning and may require emergency treatment.
Investigation priorities
Establish fluctuation, hallucinations, dream enactment, parkinsonism and their temporal relationship to cognitive decline.
Management branches
Dementia presents with visual, fluctuation, motor or sleep features.
- 1. Obtain patient and collateral descriptions of hallucinations, short-timescale alertness variation, dream enactment and motor change, documenting onset relative to dementia.
- 2. Review antipsychotic, antiemetic, sedative and dopaminergic exposures and exclude delirium, eye disease, sleep apnoea and vascular mimics.
- 3. Examine cognition by domain, eye movements, bradykinesia, rigidity, gait and orthostatic physiology and arrange structural imaging and routine dementia bloods.
- 4. If uncertainty remains clinically important, request FP-CIT SPECT or sleep testing through the specialist memory or movement service.
Key medicines
RivastigmineStart 1.5 mg orally twice daily with food and increase no more often than every two weeks towards the lowest helpful tolerated dose; a transdermal pathway may suit selected adherence or gastrointestinal problems.Monitor nausea, diarrhoea, weight loss, bradycardia, syncope, falls and tremor. Check patch technique and remove the old patch before a new one; restart low after a significant interruption.
Levodopa for disabling parkinsonismA specialist may begin a low levodopa combination dose, such as co-beneldopa 12.5/50 mg once to three times daily, and increase slowly against a defined mobility goal.Monitor hallucinations, confusion, orthostatic hypotension, nausea and dyskinesia. Avoid chasing a normal motor examination with high doses, and never stop established dopaminergic therapy abruptly.